Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck
Status:
Completed
Trial end date:
2016-03-31
Target enrollment:
Participant gender:
Summary
The primary objective of the trial is to determine, in patients who have undergone surgery
with curative intent for high-risk CSCC of the head and neck, whether there is a difference
in time to loco-regional relapse between patients treated with post-operative concurrent
chemo-radiotherapy ,consisting of Carboplatin, and post-operative radiotherapy alone. The
target sample size for the trial is 266 patients and will take 3-4 years to accrue, based on
an anticipated accrual of 80 patients/year. A further 2 years follow up is required.
Phase:
Phase 3
Details
Lead Sponsor:
Trans Tasman Radiation Oncology Group Trans-Tasman Radiation Oncology Group (TROG)
Collaborators:
Princess Alexandra Hospital, Brisbane, Australia The Royal Australian and New Zealand College of Radiologists